Strides Pharma Science (NSE:STAR) Growth Rank: 5 (As of Aug. 13, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
71 GF Score
Price ₹993.80
GF Value ₹847.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Strides Pharma Science Growth Rank?

Strides Pharma Science NSE:STAR -0.90% 71 Growth Rank is 5 as of Aug. 13, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates NSE:STAR with a GF Score™ of 71/100 and a GF Value™ of ₹847.26 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Strides Pharma Science has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Strides Pharma Science Growth Rank Related Terms

NSE:STAR vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strides Pharma Science Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Growth Rank distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Growth Rank falls into.


NSE:STAR
71GF Score
Strides Pharma Science Ltd NSE:STAR
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Strides Pharma Science (NSE:STAR) has a Growth Rank of 5 as of Aug. 13, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Strides Pharma Science and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, Strides Pharma Science's Growth Rank has ranged from 1.00 to 8.00.
Is Strides Pharma Science's Growth Rank too high?
Strides Pharma Science's current Growth Rank of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, Strides Pharma Science has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Growth Rank compare to ZTS?
Strides Pharma Science's Growth Rank of 5 can be compared against companies in the Drug Manufacturers industry. Historically, Strides Pharma Science's own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Growth Rank is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹847.26, compared to a current price of ₹993.80 — trading 17.3% above its estimated fair value. The current Growth Rank is 5, which is 67% above median its 10-year median of 3.00. Strides Pharma Science's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Growth Rank is 5 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹993.80 is trading 17.3% above its estimated GF Value™ of ₹847.26. GuruFocus considers Strides Pharma Science to be Modestly Overvalued.

Key valuation signals for NSE:STAR:

  • Growth Rank: 5 (67% above median its 10-year median of 3.00)
  • GF Value™: ₹847.26 vs. price of ₹993.80 (17.3% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
71GF Score

Get the complete analysis for NSE:STAR

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹993.80
Price
₹847.26
GF Value